<DOC>
	<DOCNO>NCT00722176</DOCNO>
	<brief_summary>A Six-Week , Randomized , Double-Blind , Parallel Group Extension Study To Evaluate The Long-Term Safety , Tolerability , And Efficacy Of Low And High Doses Of Bl-1020 Compared To Risperidone , In Schizophrenic Patients Previously Treated In Study Bl-1020 Iib For A Maximum Of Six Weeks With Bl-1020 ( High Dose , Low Dose ) , Risperidone Or Placebo</brief_summary>
	<brief_title>Extension Study To Evaluate The Long-Term Safety , Tolerability , And Efficacy Of Low And High Doses Of Bl-1020</brief_title>
	<detailed_description>This six-week , randomize , double blind , multi-center , parallel group Extension BL-1020 IIb study . In Extension Study patient hospitalize schizophrenia previously treat BL-1020 IIb study BL-1020 ( low dose : 10 mg/day ; high dose : target dose 30 mg/day ) , risperidone ( target dose : 8 mg/day ) placebo experience acute exacerbation schizophrenia . Patients complete 6 week treatment period and/or efficacy assessment Study BL-1020 IIb eligible continue double-blind treatment optional 6 week Extension Study . Approximately 220 patient enrol study : Treatment Group IE ( n=82 , 10 mg/day BL-1020 ) ; Treatment Group IIE ( n=82 : target dose 30 mg/day BL-1020 ) ; Treatment Group IIIE ( n=55 ; target dose 8 mg/day risperidone ) . Study drug ( BL-1020 risperidone ) administer orally , daily , doubleblinded manner , six-week Extension Study</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>1 . Male female , 1865 year age time entry BL1020 IIb study 2 . Has provide inform consent participate Extension Study 3 . Has complete 6 week treatment and/or complete efficacy assessment Study BL1020 IIb 4 . Females must negative serum pregnancy test , postmenopausal , fecund , must practice establish method birth control ( oral contraceptive tablet , hormonal implant device , hormone patch , injectable contraceptive , intrauterine device [ IUD ] ) least two month prior screen 5 . Females must use establish method birth control ( ) AND barrier method ( condom , diaphragm , contraceptive foam ) take study medication 6 . Has caregiver identify responsible person ( e.g. , family member , social worker , nurse ) support him/her ensure compliance treatment outpatient visit 7 . Is willing comply take prohibited medication participation study 8 . Successful completion End Study assessment BL1020 IIb 1 . Is unwilling unable provide inform consent 2 . Is unwilling unable , opinion Investigator , comply study instruction 3 . Has medical condition would put him/her risk continue study 4 . Score &gt; 9 Modified InterSePT Scale Suicidal Thinking ( Modified ISST ) 5 . Tested positive drug abuse initial 6 week treatment ( Study BL1020 IIb ) 6 . Has noncompliant study medication dose and/or study procedures initial 6 week treatment Study BL1020 IIb 7 . Is judged PI inappropriate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>